Scientific Program

Conference Series Ltd invites all the participants across the globe to attend 2nd International Congress on Contemporary Issues in Women Cancers & Gynecologic Oncology London, UK (Park Inn by Radisson London Heathrow).

Day 1 :

Keynote Forum

Edward J Pavlik

University of Kentucky, USA

Keynote: Ovarian cancer screening and the clinical surveillance of ovarian abnormalities

Time : 09:45-10:25

OMICS International Gynecologic Cancers 2017 International Conference Keynote Speaker Edward J Pavlik photo

Dr. Pavlik is a graduate of the University of Denver, and received his PhD from the University of Tennessee, Knoxville. He received a NCI Public Health Service Fellowship at the University of Illinois, Champaign Urbana, Illinois and was a Visiting Assistant Professor, Department of Physiology and Biophysics at the University of Illinois, Champaign Urbana. He is an active lecturer in the College of Medicine and organizes and mentors summer intern research including students from Denison University, Penn State University, Transylvania University, Centre College, Vassar College, the University of North Carolina, Eastern Kentucky University, Depauw University, Union College and the University of Kentucky. He is a member of the Graduate College and serves on dissertation committees for the PhD degree. Dr. Pavlik is an author on over 100 peer reviewed publications, has presented at a number of prestigious international conferences, and has been funded by the NCI, the ACS and the VA. His research focus is on ovarian cancer screening and factors that affect screening accuracy and performance. Dr. Pavlik is a member of the editorial board for: the British Journal of Medicine and Medical Research, Journal of Gynecology and Obstetrics, the Journal of Medical Oncology, the Imaging Journal of Clinical and Medical Sciences, Gynecologic and Obstetrics Research, Journal of Cancer Metastasis and Treatment, Women's Health International, Clinics in Oncology Gynecological Cancers.


Women that are positive for an ovarian abnormality in a clinical setting can have either a malignancy or a benign tumor with probability favoring the benign alternative.  Discovering a malignancy as early as possible will lead to extended survival.  Surgery on benign abnormalities results in unnecessary procedures introducing cost burdens.  Surveillance using serial ultrasonography can be used to discover if changes in the ovarian abnormality will occur that favor either a malignant or benign interpretation.  Several ovarian cancer screening trials have had experiences with changes in subclinical ovarian abnormalities in normal women that can define growth, stability or resolution and the time frame over which changes occur.  The present report examines information from screening trials, and relates it to ovarian cancer ontology, presenting arguments related to the benefits of surveillance. 

Intricacies of ovarian cancer screening are considered as ten considerations:

1.         Deciding on the number to be screened.

2.         Anticipating reductions due to death.

3.         Deciding the duration and frequency of screening.

4.         Deciding on the follow-up period.

5.         Deciding on time to surgery.

6.         Deciding on how screening cases are treated and by whom.

7.         Deciding on how to treat data.

8.         Deciding on how to assign disease specific death.

9.         Deciding how to avoid participants with late stage disease.  

10.       Deciding whether the screening tool or a screening process is being tested.

The considerations presented provide explanations of effects that have an important bearing on interpreting ovarian screening outcomes and the surveillance of ovarian abnormalities in clinical practice.

Keynote Forum

Kwong Kwok Wong

University of Texas, USA

Keynote: The challenge of targeted therapies in epithelial ovarian cancer

Time : 10:25-11:05

OMICS International Gynecologic Cancers 2017 International Conference Keynote Speaker Kwong Kwok Wong photo

Kwong-Kwok Wong, Ph.D. is a molecular biologist and completed his PhD from the Chinese University of Hong Kong. He is currently a professor in the Department of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center. His laboratory is interested in deciphering the molecular pathogenesis of ovarian cancer with a translational goal to identify biomarkers and therapeutic targets. One of his current projects supported by the UT MD Anderson Ovarian SPORE grant is to understand the molecular progression of low-grade serous ovarian cancer and to determine the resistance mechanisms of ovarian cancer to MEK inhibitors. He has published 78 peer-reviewed articles and 13 book chapters. He is also an inventor or co-inventor in 6 US issued patents. Dr. Wong is a regular member of the graduate faculty for The University of Texas Graduate School of Biomedical Sciences. He has trained graduate students and clinical fellows and has been named the Faculty Educator of the Month (August, 2016). He is an academic editor for PLOS One, a member of editorial board for American Journal of Clinical and Experimental Obstetrics and Gynecology, and the Editor-In-Chief for the Advances in Modern Oncology Research.


The mortality rate for ovarian cancer has remained roughly unchanged for the past 40 years. Various targeted therapies for
ovarian cancer are under investigation, including therapies targeting angiogenesis, DNA repair, the cell cycle, signaling pathways and immune checkpoint proteins. However, these treatments are failing to significantly improve overall survival. Ovarian cancer is a heterogeneous disease. There are five major histological subtypes of epithelial ovarian cancer: high-grade serous carcinoma (HGSC), low-grade serous carcinoma (LGSC), ovarian clear cell carcinoma (OCCC), mucinous epithelial ovarian carcinoma, and ovarian endometrioid carcinoma. TP53 mutations are present in almost all HGSCs, and BRCA1/2 mutations are present in approximately 10% of HGSCs. However, other actionable mutations are infrequent in HGSCs. On the other hand, KRAS activating mutations are present in more than 30% of LGSCs and 40% of mucinous ovarian carcinomas. PIK3CA activating mutations are present in more than 35% of OCCCs and more than 20% of ovarian endometrioid carcinomas. BRAF activating mutations are detected in both LGSCs (2-33%) and mucinous ovarian carcinomas (~10%). ARID1A, the
AT-rich interactive domain 1A gene, is mutated in more than 45% of OCCCs and more than 25% of ovarian endometrioid carcinomas. These advances in the molecular characterization of epithelial ovarian cancer have led to clinical trials targeting specific histological subtypes to overcome the challenge of this heterogeneous disease. A phase II study has been conducted to
investigate the activity of a MEK1/2 inhibitor (selumetinib) for women with recurrent LGSC. About 15% (8/52) of patients had an objective response. Next-generation sequencing of the tumor sample from a patient with a complete and striking durable
response to selumetinib identified a 15-nucleotide deletion in the MAP2K1 gene, which encodes MEK1. Another patient in the study who had a durable response had a KRAS G12V mutation. However, there is no correlation of KRAS, NRAS, or BRAF mutation status with selumetinib response. A phase II study has also been conducted to investigate the activity of mTOR inhibitor temsirolimus with carboplatin and paclitaxel as first-line therapy in patients with newly diagnosed stage III or IV OCCC. However, this regimen did not significantly increase progression-free survival at 12 months. A preclinical study by our group suggests that the sensitivity of OCCC with PIK3CA mutations to PI3K inhibitor can be affected by the co-existence of KRAS mutations. We also found that ARID1A-mutant OCCC cells express higher levels of reactive oxidative species (ROS) and are more sensitive to ROS-inducing agents than ARID1A-wild-type ovarian cancer cells. These vulnerabilities in OCCC with ARID1A mutation are waiting to be tested clinically. The results to date from targeted therapies for epithelial ovarian cancer highlight the need to identify robust predictive markers to guide the selection of patients in whom targeted drugs are most likely to be beneficial. Also, the role of adaptive responses in resistance to targeted therapy needs to be better understood.
Another challenge is finding targeted therapy for rare types of ovarian cancer. For instance, the GOG-0241 phase III trial for
patients with mucinous epithelial ovarian cancer was suspended owing to low accrual.

Keynote Forum

Annina N Wilkes

Thomas Jefferson University, USA

Keynote: Ultrasound screening of breast and gynecologic cancers

Time : 11:30-12:10

OMICS International Gynecologic Cancers 2017 International Conference Keynote Speaker Annina N Wilkes photo

Annina N Wilkes completed a Fellowship in Breast Imaging and Ultrasound at The Thomas Jefferson University Hospital and has remained on Staff there for the past 27 years as Clinical Associate Professor specializing in Breast Imaging and Diagnostic Ultrasound. She has served as Director of the Breast Imaging Center and has been actively involved in research throughout her career participating in clinical trials in digital mammography and breast ultrasound screening. She is currently involved in research in breast ultrasound contrast agents. She has served as an International Visiting Professor through the Radiologic Society of North America evaluating the best practice screening method for reducing mortality from breast and gynecologic cancer in countries with limited resources.


The death rates from breast and cervical cancer are increasing in countries with limited resources. Mammography is the gold standard for breast cancer screening with proven reduction in mortality in populations who are regularly screened. PAP and HPV testing for cervical cancer has the same proven mortality reduction in populations regularly screened. The implementation of screening programs in countries with limited resources is an ongoing work in progress, the initiation and maintenance limited by financial, infrastructural and political constraints. Breast cancer screening with ultrasound, as it has become increasingly performed and studied has been shown to diagnose early as well as invasive cancers that are small, node negative and require less extensive treatment. There is no currently accepted ultrasound screening protocol for cervical, uterine and ovarian cancer. Yet, cancer in these organs is well demonstrated by ultrasound and can be diagnosed in early stages.
The use, quality and application of ultrasound in countries with limited resources have increased in the past decade as the equipment has become less expensive, more portable, and more available. The best chance to improve cancer outcomes in these countries in the short and even long term is through interventions that are realistic, practical and cost-effective. This research evaluates the current status and potential for ultrasound screening for breast and gynecologic cancers as it would benefit populations with limited resources.

OMICS International Gynecologic Cancers 2017 International Conference Keynote Speaker Samir A Farghaly photo

Samir A Farghaly is a Professor/Physician/Scientist and national and international expert in Obstetrics and Gynecology at Joan and Sanford I Weill College of Medicine, Sandra and Edward Meyer Cancer Center and, the New York Presbyterian Hospital/Weill Cornell Medical Center- Cornell University, New York, USA. He has received his MD from London University and his PhD degree in Molecular Biology from London University. He was affiliated with major London University teaching hospitals, Columbia University College of Physicians and Surgeons/Columbia University Medical Center, New York, USA. He has been an invited speaker at several national and international conferences on Women’s Health, Molecular Genetics of Female Cancers, Gynecological Cancer, and Oncologic Radical Surgical Techniques. He is a member of several national and international societies, organizations, foundations of Women Health and Cancer. He is the founding Editor-in Chief of Insights in Gynecologic Oncology Journal, and Enliven Challenges in Cancer Detection and Therapy Journal. He acts as Senior Editor/Editor and member of editorial boards, editorial advisory boards of 18 international medical journals on Gynecological Cancers, Gene expression and Therapy, Women’s Health, and Gynecology. He acted as Guest Editor of 4 special issues of international medical journals on Oncology, Gynecology and Gene Therapy. He is a reviewer for several medical journals on Obstetrics & Gynecology, Molecular Genetics and Therapy, Oncology, and Surgery. He has published 105 articles in reputed peer review journals. He has written several book chapters, and is an author and editor of (2) books on Ovarian Cancer published in 2012, and the third one published in Nov. 2013. The fourth book on Endometrial Cancer was published in January 2015. The fifth book on Recent Advances in Diagnosis and Management Gynecologic Cancers was published in March 2016, the sixth book on Ovarian Cancer Immunotherapy will be published in November 2017, and the seventh book on Uterine Cervical Cancer will be published in Feb. 2018.


Ovarian cancer is the most lethal gynecologic malignancy. Epithelial ovarian cancer (EOC) which is the most common histologic type has 5-year survival for all stages at 45.6%. This rate increases are about 70% in the minority of patients who are diagnosed at an early stage, but declines to 35% in most patients diagnosed at advanced stage. The standard treatment is primary surgery followed by platinum-based chemotherapy. In recurrent platinum-resistant/platinum-refractory EOC, sequential single-agent salvage chemotherapy is the standard of therapy, however none achieves the desired prognostic and curative effect. Currently, the impact of targeted therapies and immunotherapies on progression-free survival and overall survival, is under investigation. A new treatment modality is needed to achieve satisfactory oncologic outcomes. Triple therapy; sensitization for immune checkpoint therapy following combined inhibition of DNMT1 and EZH2 induces ovarian cancer cells to express CXC-motif chemokine 9 (CXCL9) and CXCL10, which can stimulate T helper 1 cells. This chemokine upregulation induces the attraction of tumourinfiltrating lymphocytes (TILs), which leads to the killing of tumor cells when combined with immune checkpoint therapy such as CTLA4 immune check antibody. This regimen demonstrated significant therapeutic synergy and durable treatment responses. In conclusion, the epigenetic drugs target the epigenome, and this lessens the need for precision approaches to individualized cancer therapy.